Holen Sie sich die Stockscreener-App
10.54
0.85%
-0.09
Handel nachbörslich:
10.75
0.21
+1.99%
Armata Pharmaceuticals Inc Aktie (ARMP) Neueste Nachrichten
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
Armata Pharmaceuticals (ARMP) Projected to Post Earnings on Thursday - MarketBeat
Armata Pharmaceuticals (ARMP) CBO awarded 183,142 stock options vesting 2027–2030 - Stock Titan
Armata Pharmaceuticals (ARMP) grants director 25,640 stock options - Stock Titan
Published on: 2026-03-08 06:18:18 - baoquankhu1.vn
Will Armata Pharmaceuticals Inc. stock return to pre crisis levelsNew Guidance & Risk Controlled Swing Alerts - Naître et grandir
Will Armata Pharmaceuticals Inc. stock outperform growth indexesQuarterly Portfolio Summary & Verified Technical Trade Signals - Naître et grandir
ARMPAmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split - mx.advfn.com
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX - RTTNews
ARMP Should I Buy - Intellectia AI
Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq
H.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 By Investing.com - Investing.com Canada
ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus
Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus
Armata Pharmaceuticals stock gains on FDA designation By Investing.com - Investing.com Canada
Armata Pharmaceuticals stock gains on FDA designation - Investing.com India
Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment - marketscreener.com
Armata Gains QIDP Status for AP-SA02 Bacteremia Therapy - TipRanks
Armata Pharmaceuticals receives FDA qualified infectious disease product designation - marketscreener.com
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation - TradingView
Armata Pharmaceuticals wins FDA QIDP for AP-SA02, enabling 5 years exclusivity and Fast Track eligibility - TradingView
FDA grants QIDP designation to Armata (ARMP) phage therapy AP-SA02 - Stock Titan
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire
Growth Value: What analysts say about Armata Pharmaceuticals Inc stock2025 Breakouts & Breakdowns & Fast Gain Stock Tips - baoquankhu1.vn
Options Flow: Is HFBL a turnaround storyMarket Volume Report & AI Driven Stock Movement Reports - baoquankhu1.vn
ARMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Significant Increase in Short Interest - MarketBeat
Is Armata Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Drop Watch & Safe Investment Capital Preservation Plans - mfd.ru
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat
MACD Signal: What analysts say about Armata Pharmaceuticals Inc stockJuly 2025 Analyst Calls & Safe Capital Growth Stock Tips - baoquankhu1.vn
Armata Pharmaceuticals FY2025 EPS Boosted by HC Wainwright - MarketBeat
Aug Closing: What is RADCOM Ltds debt to equity ratioMarket Movers & High Accuracy Swing Trade Signals - baoquankhu1.vn
AI Stocks: Can Armata Pharmaceuticals Inc grow without external fundingMarket Volume Summary & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) price target increased by 33.33% to 12.24 - MSN
Phage Therapy Market Set to Witness Significant Growth - openPR.com
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX), Armata Pharmaceuticals (ARMP) and Halozyme (HALO) - The Globe and Mail
Armata Extends Innoviva Credit, Warrants and Voting Pact - The Globe and Mail
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Up 2%Time to Buy? - MarketBeat
Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - MSN
Will Armata Pharmaceuticals Inc. stock gain from lower inflationQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Published on: 2026-01-19 10:14:54 - baoquankhu1.vn
Armata Pharmaceuticals (ARMP) Price Target Increased by 33.33% to 12.24 - Nasdaq
Block Trades: Is Armata Pharmaceuticals Inc stock a smart retirement pickTrade Risk Assessment & Growth Focused Stock Pick Reports - baoquankhu1.vn
Armata Wins FDA Support to Advance Bacteriophage to Phase 3 - TipRanks
Armata Pharmaceuticals Advances AP-SA02 to Phase 3 Study - TradingView — Track All Markets
C O R R E C T I O N -- Armata Pharmaceuticals, Inc./ – Company Announcement - Financial Times
ARMP Stock Quote - richtv.io
Why Armata Pharmaceuticals Inc. (TG1N) stock is upgraded to buyJuly 2025 Weekly Recap & Target Return Focused Picks - ulpravda.ru
What valuation multiples suggest for Armata Pharmaceuticals Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - ulpravda.ru
Armata Pharmaceuticals, Inc. Common Stock (NY: ARMP - FinancialContent
Will Armata Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Trend Report & Entry and Exit Point Strategies - Улправда
Will Armata Pharmaceuticals Inc. stock continue dividend increases2025 Price Targets & Community Consensus Trade Alerts - Улправда
Trade Recap: Will Armata Pharmaceuticals Inc. stock deliver long term returnsJuly 2025 Catalysts & Accurate Entry/Exit Alerts - Улправда
Can Armata Pharmaceuticals Inc. stock attract ESG capital inflowsMarket Risk Summary & Scalable Portfolio Growth Methods - ulpravda.ru
Will Armata Pharmaceuticals Inc. stock maintain dividend yield2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
Will Armata Pharmaceuticals Inc. stock pay special dividendsMarket Sentiment Review & Real-Time Stock Movement Alerts - Улправда
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):